Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation

PHASE2CompletedINTERVENTIONAL
Enrollment

155

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Allergic Conjunctivitis
Interventions
DRUG

Prednisolone Acetate 0.12% (Pred Mild®)

Indicated for the treatment of mild to moderate noninfectious allergic and inflammatory disorders of the lid, conjunctiva, cornea, and sclera (including chemical and thermal burns). Instill one to two drops into the conjunctival sac two to four times daily. During the initial 24 to 48 hours, the dosing frequency may be increased if necessary.

DRUG

FOV1101-00

This investigational drug is a low dose cyclosporine (also known as cyclosporine A; CsA) formulation for topical ocular administration. FOV1101-00 is presented as a solution for topical ophthalmic administration in two strengths, concentration 1 or concentration 2 w/v cyclosporine in citrate buffered aqueous vehicle. Application is intended as four times per day.

DRUG

Prednisolone Acetate 1% (Pred Forte®)

PRED FORTE® is indicated for the treatment of steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. Instill one to two drops into the conjunctival sac two to four times daily. During the initial 24 to 48 hours, the dosing frequency may be increased if necessary. Care should be taken not to discontinue therapy prematurely.

DRUG

Placebo

The vehicle is an eye drop that contains only the inactive ingredients of FOV1101-00.

Trial Locations (1)

01810

Ora, Andover

Sponsors
All Listed Sponsors
lead

Fovea Pharmaceuticals SA

INDUSTRY